• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

Fibrinogen (Factor I) Deficiencies

This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.

CSL Behring & Therapies

Coagulation therapy is the foundation of CSL Behring’s broad range of therapies.

Learn More


Fibrinogen (factor I) replacement therapy is used in the following situations:13

  • Treating spontaneous bleeding (treatment aims to achieve plasma fibrinogen levels of at least 1 g/l or at least 1.5 g/l to treat bleeding during major episodes, such as central nervous system (CNS) bleeding 7
  • Preventing perioperative bleeding (surgery, dentistry, other invasive interventions), and bleeding associated with childbirth
  • Preventing bleeding in individuals at risk (dose every 2–4 weeks), for example, following a CNS bleed (secondary prophylaxis) or to prevent early placental, ante- and post-partum bleeding during pregnancy
The table below summarizes the three types of products available for replacement fibrinogen therapy.

Fibrinogen concentrate 13-14, 15 Cryoprecipitate 13, 14 Fresh frozen plasma 11, 16
  • High purity concentrate of the deficient factor
  • Clinical experience limited but growing with wider availability and increasing evidence base
  • Dedicated viral inactivation steps in manufacturing process minimize risk of pathogen transmission
  • Offers standard fibrinogen content for accurate dosing
  • Thawing not required
  • Development of thrombosis is very rare
  • The mainstay of treatment when fibrinogen concentrate is unavailable
  • Variable fibrinogen content, and risk of hypercoagulability due to high amounts of factor VIII
  • Typically, 10 single bags needed to raise plasma fibrinogen level by 0.3 to 1g/l (depending on fibrinogen concentration) in an adult
  • No viral inactivation process; risk of pathogen transmission from donor to patient, particularly blood-borne viruses
  • Some risk of adverse reactions such as transfusion-related acute lung injury (TRALI)
  • Must be thawed, delaying infusion time
  • Low levels of fibrinogen mean large volume must be given to patient, risking hypervolemia, TRALI and other side effects
  • Considered inappropriate for replacing fibrinogen in many countries

CSL Behring Products

For more information about Factor I deficiency treatment options, please visit the following resources*:

Package Inserts

Product Websites

RiaSTAP.com (United States)

*Not all products are available in every country. To learn what products are available in your country, visit your CSL Behring country site.

Last Updated: 4/23/2015 4:28 PM
  • E-mail
  • Print
  • Share